Cargando…
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
RATIONALE & OBJECTIVE: Venglustat, a glucosylceramide synthase inhibitor, inhibits cyst growth and reduces kidney failure in mouse models of autosomal dominant polycystic kidney disease (ADPKD). STAGED-PKD aims to determine the safety and efficacy of venglustat and was designed using patient enr...
Autores principales: | Perrone, Ronald D., Hariri, Ali, Minini, Pascal, Ahn, Curie, Chapman, Arlene B., Horie, Shigeo, Knebelmann, Bertrand, Mrug, Michal, Ong, Albert C.M., Pei, York P.C., Torres, Vicente E., Modur, Vijay, Gansevoort, Ronald T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529969/ https://www.ncbi.nlm.nih.gov/pubmed/36204243 http://dx.doi.org/10.1016/j.xkme.2022.100538 |
Ejemplares similares
-
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2023) -
Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021) -
Cure of ADPKD by Selection for Spontaneous Genetic Repair Events in Pkd1-Mutated iPS Cells
por: Cheng, Li-Tao, et al.
Publicado: (2012) -
Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants
por: Hallows, Kenneth R., et al.
Publicado: (2022) -
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)